Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Wednesday, September 30, 2026

⚡ Executive Takeaway

One day, two datasets aging in opposite directions. Lilly's retatrutide numbers come from 1,152 randomized patients followed for 80 weeks, and the length is the point: the weight curve held to the end, the placebo arm did its job, and the dataset will walk into the FDA next year with little left to prove about durability. uniQure's problem is the mirror image. Its comparison was never randomized, and at 48 months the external control has decayed underneath it, with more than half the control data missing and the remaining patients plausibly the healthier half. The 44% may understate the drug or flatter it; that is exactly what an external control cannot tell you at four years. The transferable lesson for anyone holding accelerated approval paper: randomized evidence compounds with time, external control evidence erodes with it, and the FDA has now watched this happen twice in seven days, counting the I-DXd withdrawal. The delivery layer through line gets its next dated test in Milan this morning with OCTANE; Friday we grade the week.

The full dose tables, the 36 versus 48 month comparison, and the day's movers, all below. 👉 Read Full Analysis

💉 Obesity and Diabetes

Retatrutide posted the deepest weight loss yet reported in a type 2 diabetes population. LLY

Lilly's triple agonist of GIP, GLP-1, and glucagon receptors cut body weight 12.7%, 19.1%, and 20.8% at the 4, 9, and 12 mg doses versus 4.0% for placebo over 80 weeks in TRIUMPH-2, with A1c reductions up to 1.6 points, per Lilly's release and the simultaneous Lancet publication. The milestone numbers carry the story: 59.5% of 12 mg patients no longer met BMI criteria for obesity, and 40.0% reached a normal range A1c. People with type 2 diabetes reliably lose less weight on incretins than people without it; a 20.8% average in this population approaches what first generation agents managed in obesity alone. Discontinuations for adverse events ran 7.7% at 12 mg. Lilly plans a US submission in Q1 2027. The release crossed after the close, so Wednesday is the first reaction session.

🧠 Gene Therapy

uniQure's four year data weakened its own case in the middle of its FDA review. QURE

At 48 months, AMT-130's slowing of Huntington's progression on the composite cUHDRS scale fell to 44% and lost statistical significance (p=0.144), down from 80% at 36 months, the dataset the pending BLA rests on, per uniQure's release. Total functional capacity held at 61% slowing (nominal p=0.008). The company's defense is about the comparator, not the drug: more than half the external control data was missing by month 48, and dropouts were declining faster than those who stayed. The FDA had deemed the 36 month data acceptable for an accelerated approval review at a June Type B meeting; an acceptance decision had been expected around early November. QURE closed at 24.51, down 37.3%, our arithmetic from settled closes, in the first reaction session.

⚖️ Litigation

Beam says its base editing secrets walked out the door and reappeared in two rivals. BEAM

Beam Therapeutics filed suit September 25 in federal court in Massachusetts against YolTech Therapeutics and Serapha Bio, alleging that scientist Zi Jun "Emma" Wang secretly founded YolTech while employed at Beam in 2021 and 2022 and accessed dozens of internal records outside her ordinary work, per the complaint as reported by BioPharma Dive, STAT, and Bloomberg Law. The overlap is not abstract: Beam's BEAM-302 and Serapha's SERP-01 target the same alpha-1 antitrypsin deficiency mutation. Serapha, which launched in June with $230 million from RA Capital and RTW, says it categorically refutes the claims. After a year in which the industry priced Chinese biotech assets into every pipeline, the provenance of the underlying technology just became a litigated question.

🏛️ Policy

Pharma's lobby hired a dealmaker one day after the tariff wall went general.

PhRMA named Eric Cantor, former House Majority Leader and current Moelis Vice Chairman, its next president and CEO, effective November 9, with Stephen Ubl departing January 15, 2027, per PhRMA's release. The profile is the message: the industry's defining exposures are now settled in negotiated deals rather than legislative fights. Meanwhile the Section 232 tariff's general effective date arrived Monday with exemption architecture as its first observable product: specified specialty drugs from 20 jurisdictions enter at zero duty under the September 23 Commerce notice, per Business Standard, and generics sit outside Section 232 entirely. No company disclosed a same day financial impact as of our Tuesday evening check; we report observations, not predictions.

🧪 The Amylin Lane

Petrelintide chose tolerability, while CagriSema's body composition data stayed offstage. NVO | RHHBY

Zealand and Roche's amylin analog delivered up to 10.7% weight loss at 42 weeks with gastrointestinal side effects at rates similar to placebo in Phase 2 ZUPREME-1, per Zealand's release and the Lancet Diabetes and Endocrinology publication; at the maximally effective dose there were no vomiting cases and no GI discontinuations, and a global Phase 3 program is underway. Trade coverage notes the dose response plateaued at the middle dose. The same day retatrutide moved the efficacy ceiling to twice that number, which is the two segment obesity market in a single tape. Novo's REIMAGINE 1 body composition late breaker was presented Tuesday in Milan, but Novo issued no release and no coverage with verifiable figures had appeared by our Tuesday evening check; we will print the numbers once corroborated.

💰 Capital and Approvals

Viking banked $575 million into a falling tape, and a Stockholm rare disease company took home an approval and a voucher. VKTX | SMMT

Viking closed its concurrent upsized offerings with underwriters exercising their options in full on both legs: gross proceeds approximately $575.0 million, net approximately $547.8 million, for VK2735 and VK3019, per the company's release. VKTX closed Tuesday at 31.81, 9.1% below the $35.00 offer, our arithmetic. Egetis Therapeutics won FDA approval for Emcitate (tiratricol), the first US therapy for MCT8 deficiency, a rare X linked disorder with a median life expectancy near 35 years, and received a rare pediatric disease priority review voucher it expects to explore monetizing, potentially in Q4, per the company's release and the FDA's own announcement. Elsewhere on the tape: SMMT added 5.9% to 16.39 in its first session after the AstraZeneca investment, and Kodiak's Monday repricing held, closing up 1.3% at 91.12.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

Evidence ages, and Tuesday showed both directions at once; the difference was randomization. Milan runs through Thursday, and Friday we grade the delivery layer against everything this week produced. What are you watching? Reply to this email.

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →